Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483027 · ClinicalTrials.gov registry record · NA
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 428
- Enrollment target
NCT01483027 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 428 participants.
The verdict
NCT01483027, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 428 participants
- Enrollment target
Study Summary
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
Interventions
- DEVICE TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2012-01 |
| Est. Completion | 2020-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01483027
The ClinicalTrials.gov registry entry for NCT01483027 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere is the first listed.
NCT01483027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01483027 about?
NCT01483027 is a clinical study titled "Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer". The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
What is the current status of trial NCT01483027?
This trial is currently completed. It is a NA study. The enrollment target is 428 participants. The study started on 2012-01. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT01483027?
The interventions under investigation include: TheraSphere (DEVICE).
Who is sponsoring clinical trial NCT01483027?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.